Joe Goldman represents clients on a wide range of international and domestic tax matters. His practice involves structuring and documenting international transactions (including mergers and acquisitions, post-acquisition integration of global businesses, restructurings, and intellectual property licensing) and defending disputes with the IRS.

Joe's primary concentration is in cross-border taxation, and he works with clients to maximize tax efficiency by developing specialized planning for deferral, foreign tax credits, transfer pricing, and profit repatriation. He also works with private equity clients, strategic investors, and hedge funds to structure their investments in the most tax-efficient manner.

In the pharmaceutical industry, Joe was the lead outside tax counsel for Celgene in structuring the acquisition of Abraxis, Pharmion, Gloucester, and other investments and collaboration arrangements exceeding $7 billion and had a leading role in structuring Pfizer's acquisition of more than $150 billion in businesses and its disposition of nearly $25 billion in non-core assets. Representative clients include Celgene, Dow Corning, High Road Capital, One Equity Partners, Patrón Spirits, Riverside, and Sarepta Therapeutics.

Joe is listed as a leading tax attorney in Chambers USA: America's Leading Lawyers for Business and described as an individual who has "fabulous knowledge of the business, a great work ethic and honesty." Joe is a member of the American Bar Association (Taxation Section), the District of Columbia Bar, and the New York State Bar Association. He has lectured at conferences on numerous topics involving federal and international taxation.